Emerging treatments in Castleman disease – a critical appraisal of siltuximab [PDF]
Biologics: Targets and Therapy, 2016 Castleman disease (CD) is a rare, heterogeneous lymphoproliferative disorder for which no standard of care currently exists. Evidence that the pathophysiology of CD is fueled by excessive interleukin-6 (IL-6) has led to considerable interest in therapeutic targeting of this cytokine.
Koff, Jean L, Lonial, Sagar
core +4 more sources
Successful treatment of disseminated Rosai-Dorfman disease with siltuximab
Haematologica, 2018 Rosai-Dorfman disease (RDD) is a rare, macrophage-related disorder of unknown cause that presents as a localized or systemic disorder involving lymph nodes and other organs. RDD is often self-limiting, however, sometimes permanent or even fatal.
Hannah Lee +5 more
doaj +3 more sources
Efficacy of Siltuximab and 1,927 nm Fractional Laser for the Treatment of Cutaneous Manifestations in Castleman’s Disease: The Role of Dermoscopy and Reflectance Confocal Microscopy for Lesion Evaluation [PDF]
Case Reports in DermatologyIntroduction: Multicentric Castleman’s disease (MCD) with cutaneous involvement has rarely been discussed in dermatologic literature, with few reports. Cutaneous lesions in MCD may induce deep scars, causing a significant impact in the daily life of the ...
Giovanni Paolino +9 more
doaj +3 more sources
Impact of siltuximab on patient-related outcomes in multicentric Castleman’s disease [PDF]
Patient Related Outcome Measures, 2018 Multicentric Castleman's disease (MCD) is a rare, widespread lymphoproliferative disorder and a life-threatening disease involving hyperactivity of the immune system, excessive proinflammatory cytokine release, immune cell proliferation, and organ system dysfunction.
Jenna Sitenga +3 more
core +5 more sources
The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease [PDF]
The Korean Journal of Internal Medicine, 2021 Background/Aims Idiopathic multicentric Castleman disease (iMCD) comprises approximately 30% of all cases of Castleman disease. It is characterized by constitutional symptoms, enlarged lymph nodes at multiple anatomical sites, and laboratory test ...
Gi-June Min +16 more
doaj +1 more source
The Evolution and Recent Advances in Diagnostic Criteria for Idiopathic Multicentric Castleman Disease. [PDF]
Am J HematolIdiopathic Multicentric Castleman Disease. ABSTRACT Idiopathic multicentric Castleman disease (iMCD) is a rare cytokine‐driven disorder characterized by systemic inflammation, organ dysfunction, and altered lymph node microscopic architecture. Over the past decade, diagnostic criteria have evolved significantly, integrating clinical, histopathological,
Alnoor F +11 more
europepmc +2 more sources
Expert Perspective: Diagnosis and Treatment of Castleman Disease. [PDF]
Arthritis RheumatolCastleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Chen LYC, Zhang L, Fajgenbaum DC.
europepmc +2 more sources
Rapid Relapse of Idiopathic Multicentric Castleman Disease After Siltuximab Discontinuation in a Case with Complete Remission for More Than 10 Years [PDF]
Turkish Journal of HematologyYuhan Gao, Jian Li, Lu Zhang
doaj +2 more sources
When Autoimmunity Meets Malignancy: A Rare Case of Concomitant Systemic Lupus and Multiple Myeloma. [PDF]
Clin Case RepABSTRACT The association between systemic lupus erythematosus (SLE) and multiple myeloma (MM) is rare, with fewer than 20 cases reported in the literature, raising questions about the link between chronic immune dysregulation and oncogenesis. We report the case of a 43‐year‐old Malagasy woman in whom a monoclonal β2‐globulin spike, incidentally ...
Ratsimbazafy SJN +7 more
europepmc +2 more sources
Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report
Therapeutic Advances in Hematology, 2022 Human herpes virus-8 (HHV8)-negative, idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder sustained by pro-inflammatory cytokines, including interleukin-6 (IL-6).
Evan Lang +3 more
doaj +1 more source